L
Legend Biotech
Multinational biopharmaceutical company focused on discovering and developing cutting-edge cell-based therapies
About Legend Biotech
Legend Biotech is a biotechnology company that focuses on the development and commercialization of innovative cell therapies to treat serious and hard-to-treat diseases, including hematological malignancies and solid tumors. These are types of cancers that affect the blood, bone marrow, and lymph nodes, as well as solid masses of tissue. The company is technology agnostic, meaning it doesn't limit itself to one particular technology, but rather explores multiple technologies in its quest for effective treatments.
The company operates in the global healthcare market, specifically in the sector of personalized medicine. Its business model involves the discovery, development, and commercialization of novel therapies. This means that Legend Biotech not only discovers and develops new treatments, but also takes them to market, selling them to healthcare providers and patients.
Legend Biotech's revenue is generated through the licensing and sale of its therapies. For instance, it recently announced an exclusive global license agreement for certain CAR-T therapies. CAR-T therapy is a type of treatment that modifies a patient's own cells to fight cancer.
The company also regularly communicates with investors, hosting conference calls to discuss financial results and business highlights. This indicates a commitment to transparency and investor relations.
In summary, Legend Biotech is a comprehensive cell therapy company that uses innovative technologies to develop and commercialize treatments for serious and intractable diseases.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Bridgewater Township, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Johnson & Johnson Innovation
Lilly Asia Ventures
RA Capital Management
Hudson Bay Capital Management
Vivo Capital
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
94 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Legend Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Legend Biotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.